Citigroup Inc Kal Vista Pharmaceuticals, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Citigroup Inc holds 305,504 shares of KALV stock, worth $2.59 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

305,504

Previous 286,064 6.8%

Holding current value

$2.59 Million

Previous $3.37 Million 4.99%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$9.46 - $15.39 $183,902 - $299,181	19,440 Added 6.8%	305,504 $3.54 Million
Q2 2024 Aug 12, 2024	BUY	$10.35 - $12.49 $32,923 - $39,730	3,181 Added 1.12%	286,064 $3.37 Million
Q1 2024 May 10, 2024	BUY	$11.07 - $16.04 $10,782 - $15,622	974 Added 0.35%	282,883 $3.35 Million
Q4 2023 Feb 09, 2024	BUY	$7.58 - $12.25 $37,831 - $61,139	4,991 Added 1.8%	281,909 $3.45 Million
Q3 2023 Nov 09, 2023	SELL	$8.95 - $11.35 $204,865 - $259,801	-22,890 Reduced 7.63%	276,918 $2.67 Million
Q2 2023 Aug 10, 2023	BUY	$7.73 - $10.57 $177,032 - $242,074	22,902 Added 8.27%	299,808 $2.7 Million
Q1 2023 May 11, 2023	SELL	$6.3 - $8.39 $1,039 - $1,384	-165 Reduced 0.06%	276,906 $2.18 Million
Q4 2022 Feb 09, 2023	BUY	$4.2 - $14.24 $1.16 Million - $3.94 Million	276,402 Added 41315.7%	277,071 $1.87 Million
Q3 2022 Nov 10, 2022	SELL	$9.85 - $16.83 $14,558 - $24,874	-1,478 Reduced 68.84%	669 $10,000
Q2 2022 Aug 10, 2022	SELL	$8.16 - $15.1 $51,326 - $94,979	-6,290 Reduced 74.55%	2,147 $21,000
Q1 2022 May 12, 2022	SELL	$11.2 - $16.97 $511,727 - $775,359	-45,690 Reduced 84.41%	8,437 $124,000
Q4 2021 Feb 10, 2022	BUY	$12.36 - $18.28 $310,718 - $459,540	25,139 Added 86.72%	54,127 $716,000
Q3 2021 Nov 10, 2021	BUY	$17.11 - $24.49 $495,984 - $709,916	28,988 New	28,988 $506,000

Others Institutions Holding KALV

# of Institutions

125

Shares Held

47.8M

Call Options Held

551K

Put Options Held

110K

View Full List

About KalVista Pharmaceuticals, Inc.

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $208M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

More about KALV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account